论文部分内容阅读
目的评价哌拉西林他唑巴坦(PIPC/TAZ)微泵持续输注治疗医院获得性肺炎的临床疗效和细菌学疗效。方法选择104例确诊为医院获得性肺炎的住院患者,采用前瞻开放性随机对照研究方法,试验组和对照组各52例。试验组给予PIPC/TAZ 3.0g/0.75g,q8h,微泵静脉持续输注3h;对照组给予PIPC/TAZ 3.0g/0.75g,q8h,静脉滴注30min。结果治疗后,试验组与对照组的总有效率分别为90.2%和72.5%,细菌清除率分别为87.5%和68.4%,2组间差异均具统计学意义(P<0.05);急性生理学及慢性健康状况Ⅱ系统评分均较治疗前改善,治疗后2组间差异有统计学意义(P<0.01);试验组平均疗程和住院时间均较对照组缩短,差异具有统计学意义(P<0.01)。结论 PIPC/TAZ微泵持续静脉输注3h治疗医院获得性肺炎,能显著提高临床疗效和细菌学疗效,缩短转归时间。
Objective To evaluate the clinical efficacy and bacteriological efficacy of continuous infusion of piperacillin and tazobactam (PIPC / TAZ) in hospital-acquired pneumonia. Methods A total of 104 inpatients with confirmed hospital-acquired pneumonia were selected. A prospective open-label randomized controlled study was conducted. The experimental group and the control group received 52 cases each. The experimental group was given PIPC / TAZ 3.0g / 0.75g, q8h, micro-pump venous infusion for 3h; the control group was given PIPC / TAZ 3.0g / 0.75g, q8h, intravenous infusion 30min. Results After treatment, the total effective rates of the experimental group and the control group were 90.2% and 72.5% respectively, and the bacterial clearance rates were 87.5% and 68.4% respectively. There was significant difference between the two groups (P <0.05); acute physiology and The scores of chronic health conditionⅡwere improved compared with that before treatment, and there was significant difference between the two groups after treatment (P <0.01). The mean duration of treatment and hospital stay in experimental group were shorter than those in control group (P <0.01) ). Conclusion PIPC / TAZ micro-pump continuous intravenous infusion of 3h treatment of hospital-acquired pneumonia can significantly improve the clinical efficacy and bacteriological efficacy and shorten the prognosis.